Iconovo has revealed that it has received a grant of $883,800 from the Bill & Melinda Gates Foundation to develop a low-cost device that can enable the delivery of medical compounds to the full respiratory tract.
Iconovo AB (publ), which develops complete inhalation products for a global market, and Respiratorius AB (publ), which develops drug candidates for the treatment of COPD, and other common diseases, announced today that they have signed an agreement for the development of an inhalation formulation as well as an inhalation product for phase I studies for Respiratorius drug candidate RES030-085 within the RESP9000 project for the treatment of COPD and severe asthma.